Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers

The advent of molecular profiling has revolutionized the treatment of lung cancer by comprehensively delineating the genomic landscape of the epidermal growth factor receptor (EGFR) gene. Drug resistance caused by EGFR mutations and genetic polymorphisms of drug metabolizing enzymes and transporters...

Descripción completa

Detalles Bibliográficos
Autores principales: Kolesar, Jill, Peh, Spencer, Thomas, Levin, Baburaj, Gayathri, Mukherjee, Nayonika, Kantamneni, Raveena, Lewis, Shirley, Pai, Ananth, Udupa, Karthik S., Kumar AN, Naveena, Rangnekar, Vivek M., Rao, Mahadev
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8867675/
https://www.ncbi.nlm.nih.gov/pubmed/35209919
http://dx.doi.org/10.1186/s12943-022-01534-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8867675/
https://www.ncbi.nlm.nih.gov/pubmed/35209919
http://dx.doi.org/10.1186/s12943-022-01534-8

Ejemplares similares